Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Emibetuzumab
DRUG
2 trials
Sponsors
Eli Lilly and Company
Conditions
Advanced Cancer
Carcinoma, Non-Small-Cell Lung
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Hepatocellular Cancer
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Phase 1
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Completed
NCT02082210
Eli Lilly and Company
Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma +3
Start: 2014-03-07
End: 2018-01-24
Updated: 2020-12-19
Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
Completed
NCT01900652
Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
Start: 2013-08-31
End: 2016-03-31
Updated: 2019-09-18
Related Papers
Abstract CT090: A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors
Cancer Research
2017-07-01
1 citations
A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.
Journal of Clinical Oncology
2016-05-20
31 citations
Emibetuzumab plus ramucirumab: Simultaneous targeting of MET and VEGFR-2 in patients with advanced hepatocellular cancer in a phase 1b/2 study.
Journal of Clinical Oncology
2016-02-01
4 citations